• Wrong document? Swap it for free
  • Written by students who passed
  • Immediately available after payment
  • Read online or as PDF
Sell
Where do you study
Your language
Document preview thumbnail
Preview 2 out of 15 pages
Exam (elaborations)

RAC

Document preview thumbnail
Preview 2 out of 15 pages

Administrative Procedure Act federal law enacted in 1946, "notice and comment rulemaking" 1906: The Pure Food and Drug Act (PFDA) interstate commerce labeling 1912 Pure Food and Drug Act revised in 1912, stated that a drug was misbranded if its label contained a "false and fraudulent" statement regarding "curative or therapeutic effect." 1938 FD&C Act • extended control to cosmetics and therapeutic devices • required new drugs to be shown safe before marketing, beginning a new system of drug regulation • eliminated the Sherley Amendment requirement to prove intent to defraud in drug misbranding cases Durham-Humphrey Amendment of 1951 • Created a distinction between "OTC" and "Legend Drugs". • Legend Drugs can only be dispensed with a valid Prescription.. • Required Legend Drugs to carry the statement: "Caution: Federal law prohibits dispensing without a prescription.". • Most people refer to Legend drugs simply as "Prescription Drugs". • The emphasis on this act was to insure safety thru qualified medical supervision. Kefauver-Harris Amendments of 1962 efficacy as well as safety informed consent for research subjects FDA regulates advertising of rx drugs established GMP Drug advertising from FTC to FDA Medical Device Amendments of 1976 -classification of devices according to their function -premarket approval -establishment of performance standards -conformance with GMP regulations -adherence to record and reporting requirements Safe Medical Devices Act of 1990 Postmarketing Authority User Facilities Recall Authority MDUFMA, Medical Device User Fee and Modernization Act of 2002 Medical Device User Fee and Modernization Act of 2002: Similar to the Prescription Drug User Fee Act (PDUFA) in many ways. Requires that was driven by the need to speed up the Premarket Approval (PMA) device and 510(k) clearances. Under MDUFMA, fees were established for PMAs, product development protocols, biologics license applications (BLA), certain supplements and 510(k)s in order to speed up the review processes. The Medical Device User Fee Amendments of 2012 Expanded user fees and performance goals Orphan Drug Act of 1983 Provides incentives to promote research, approval, and marketing of drugs needed for the treatment of rare diseases. Hatch-Waxman Act of 1984 Encouraged the creation of both generic and new medications by streamlining the process for generic drug approval and by extending patent licenses. Prescription drug user fee act of 1992 This act states that manufacturers must pay a user fee along with each drug that is marketed, facility that manufacturers drugs, and each app from approval.The money is used to hire drug reviewers and facilitate the drug approval process. Food and Drug Administration Modernization Act of 1997 additional authority for monitoring the progress of drug and biologic postmarketing studies The law codified the expedited review policy for certain medical devices, amended and clarified the humanitarian device provisions of SMDA FDA to recognize international or other national standards Agreement Meetings and Determination Meetings Pediatric Research Equity Act of 2003 act that authorizes the FDA to require research of pediatric uses for new drugs FDAAA 2007 Required registration FDAAA reauthorized a number of key programs, including PDUFA, MDUFMA and PREA 21 CFR 0-99 Protection of Human Subjects 21 CFR 100s Food 21 CFR 200s Labeling, CGMPs, Controlled Substances 21 CFR 300s Human Drugs 21 CFR 500s Animal Drugs 21 CFR 600s Biologics 21 CFR 800s Devices 21 CFR 1270 Human Tissues for Transplant 21 CFR 1271 Human Cell and Tissue Products 21 CFR 820 Quality System (QS) Regulation/Medical Device Good Manufacturing Practices Pathway: Right to Reference Original NDA = NDA Supplment Pathway: No right of Reference to Original NDA= 505(b)(2) Pathway: Similar to RLD, Same Labeling Suitability Petition Pathway: Same as RLD ANDA (CMC, Fasted and Fed BE, Crossover) AKA: ANDA 505(j) AKA: NDA Submission with no right of reference 505(b)(2) AKA: New NDA 505(b)(1) ANDA Paragraph 1 Patent information has not been filed ANDA Paragraph 2 Patent has expired ANDA Paragraph 3 Patent will expire on x date ANDA Para


Document information

Uploaded on
June 6, 2024
Number of pages
15
Written in
2023/2024
Type
Exam (elaborations)
Contains
Questions & answers
$11.99

Wrong document? Swap it for free Within 14 days of purchase and before downloading, you can choose a different document. You can simply spend the amount again.
Written by students who passed
Immediately available after payment
Read online or as PDF

Sold
1
Followers
0
Items
1124
Last sold
-



Why students choose Stuvia

Created by fellow students, verified by reviews

Quality you can trust: written by students who passed their tests and reviewed by others who've used these notes.

Didn't get what you expected? Choose another document

No worries! You can instantly pick a different document that better fits what you're looking for.

Pay as you like, start learning right away

No subscription, no commitments. Pay the way you're used to via credit card and download your PDF document instantly.

Student with book image

“Bought, downloaded, and aced it. It really can be that simple.”

Alisha Student

Working on your references?

Create accurate citations in APA, MLA and Harvard with our free citation generator.

Working on your references?

Frequently asked questions

Whoops! We can’t load your doc right now. Try again or contact support.